FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127788151> ?p ?o ?g. }

• W2127788151 endingPage "1766" @default.
• W2127788151 startingPage "1760" @default.
• W2127788151 abstract "This phase II study was undertaken to define the efficacy and pharmacodynamics of R115777, a farnesyl transferase inhibitor, in the first-line treatment of patients with advanced non-small-cell lung cancer.Forty-four patients with measurable stage IIIB (pleural effusion) or stage IV disease received 193 courses of treatment (median, 2.0; range, 1 to 22) with R115777 300 mg administered orally twice daily for 21 of every 28 days. Buccal mucosa samples and peripheral blood mononuclear cells (PBMCs) were collected before and after 8 days of treatment to evaluate inhibition of farnesyl transferase in vivo.No objective complete or partial responses were documented. Seven patients (16%; 95% confidence interval [CI], 8% to 31%) had disease stabilization for greater than 6 months. Median survival was 7.7 months (95% CI, 6.5 to 10.5) and time to progression was 2.7 months (95% CI, 1.9 to 3.1). The most severe toxicity was neutropenia (9% grade 3, 7% grade 4) and the most common toxicities were anemia (50% grade 1 or 2, 5% grade 3) and anorexia (50% grade 1 or 2, 2% grade 3). Mild peripheral neuropathy occurred in 25% of patients. Evidence of farnesyl transferase inhibition was documented in 83% of patients.Single-agent R115777 was well tolerated in patients with advanced NSCLC, but demonstrated minimal clinical activity. Inhibition of farnesylation in vivo was consistently documented. On the basis of promising results of farnesyl transferase inhibitor combinations with standard chemotherapy agents, future studies of this agent in NSCLC should be in combination with systemic chemotherapy." @default.
• W2127788151 created "2016-06-24" @default.
• W2127788151 creator A5000304798 @default.
• W2127788151 creator A5007148032 @default.
• W2127788151 creator A5016743645 @default.
• W2127788151 creator A5022511085 @default.
• W2127788151 creator A5027165899 @default.
• W2127788151 creator A5041114807 @default.
• W2127788151 creator A5051650281 @default.
• W2127788151 creator A5054370710 @default.
• W2127788151 creator A5060104863 @default.
• W2127788151 creator A5063904421 @default.
• W2127788151 creator A5063976463 @default.
• W2127788151 date "2003-05-01" @default.
• W2127788151 modified "2023-10-16" @default.
• W2127788151 title "Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer" @default.
• W2127788151 cites W126176001 @default.
• W2127788151 cites W1563425172 @default.
• W2127788151 cites W194463696 @default.
• W2127788151 cites W1955547739 @default.
• W2127788151 cites W1989203819 @default.
• W2127788151 cites W2000743805 @default.
• W2127788151 cites W2005041472 @default.
• W2127788151 cites W2008431826 @default.
• W2127788151 cites W2017098460 @default.
• W2127788151 cites W2026419785 @default.
• W2127788151 cites W2029409133 @default.
• W2127788151 cites W2036699032 @default.
• W2127788151 cites W2058729896 @default.
• W2127788151 cites W2060082191 @default.
• W2127788151 cites W2068466600 @default.
• W2127788151 cites W2100545037 @default.
• W2127788151 cites W2102901804 @default.
• W2127788151 cites W2137343757 @default.
• W2127788151 cites W21378047 @default.
• W2127788151 cites W2139248078 @default.
• W2127788151 cites W2145978772 @default.
• W2127788151 cites W2156654096 @default.
• W2127788151 cites W2255894651 @default.
• W2127788151 cites W2318112795 @default.
• W2127788151 cites W4232534952 @default.
• W2127788151 cites W4293241248 @default.
• W2127788151 doi "https://doi.org/10.1200/jco.2003.09.075" @default.
• W2127788151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12721252" @default.
• W2127788151 hasPublicationYear "2003" @default.
• W2127788151 type Work @default.
• W2127788151 sameAs 2127788151 @default.
• W2127788151 citedByCount "183" @default.
• W2127788151 countsByYear W21277881512012 @default.
• W2127788151 countsByYear W21277881512013 @default.
• W2127788151 countsByYear W21277881512014 @default.
• W2127788151 countsByYear W21277881512015 @default.
• W2127788151 countsByYear W21277881512016 @default.
• W2127788151 countsByYear W21277881512017 @default.
• W2127788151 countsByYear W21277881512018 @default.
• W2127788151 countsByYear W21277881512019 @default.
• W2127788151 countsByYear W21277881512020 @default.
• W2127788151 countsByYear W21277881512021 @default.
• W2127788151 countsByYear W21277881512022 @default.
• W2127788151 countsByYear W21277881512023 @default.
• W2127788151 crossrefType "journal-article" @default.
• W2127788151 hasAuthorship W2127788151A5000304798 @default.
• W2127788151 hasAuthorship W2127788151A5007148032 @default.
• W2127788151 hasAuthorship W2127788151A5016743645 @default.
• W2127788151 hasAuthorship W2127788151A5022511085 @default.
• W2127788151 hasAuthorship W2127788151A5027165899 @default.
• W2127788151 hasAuthorship W2127788151A5041114807 @default.
• W2127788151 hasAuthorship W2127788151A5051650281 @default.
• W2127788151 hasAuthorship W2127788151A5054370710 @default.
• W2127788151 hasAuthorship W2127788151A5060104863 @default.
• W2127788151 hasAuthorship W2127788151A5063904421 @default.
• W2127788151 hasAuthorship W2127788151A5063976463 @default.
• W2127788151 hasConcept C126322002 @default.
• W2127788151 hasConcept C2776256026 @default.
• W2127788151 hasConcept C2776694085 @default.
• W2127788151 hasConcept C2777063308 @default.
• W2127788151 hasConcept C71924100 @default.
• W2127788151 hasConcept C90924648 @default.
• W2127788151 hasConcept C98274493 @default.
• W2127788151 hasConceptScore W2127788151C126322002 @default.
• W2127788151 hasConceptScore W2127788151C2776256026 @default.
• W2127788151 hasConceptScore W2127788151C2776694085 @default.
• W2127788151 hasConceptScore W2127788151C2777063308 @default.
• W2127788151 hasConceptScore W2127788151C71924100 @default.
• W2127788151 hasConceptScore W2127788151C90924648 @default.
• W2127788151 hasConceptScore W2127788151C98274493 @default.
• W2127788151 hasIssue "9" @default.
• W2127788151 hasLocation W21277881511 @default.
• W2127788151 hasLocation W21277881512 @default.
• W2127788151 hasOpenAccess W2127788151 @default.
• W2127788151 hasPrimaryLocation W21277881511 @default.
• W2127788151 hasRelatedWork W1967103478 @default.
• W2127788151 hasRelatedWork W2032912323 @default.
• W2127788151 hasRelatedWork W2316813997 @default.
• W2127788151 hasRelatedWork W2326367365 @default.
• W2127788151 hasRelatedWork W2355443663 @default.
• W2127788151 hasRelatedWork W2372561159 @default.
• W2127788151 hasRelatedWork W2375344515 @default.

• next